Towards a Reference Case for Use in Future Economic Evaluations of Interventions in Osteoarthritis

Journal of Rheumatology

Volumn 30, Issue SUPPL. 68, 2003, Pages 26-30

  Drummond, Michael ^a   Maetzel, Andreas ^b,c   Gabriel, Sherine ^d   March, Lyn ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTON PUMP INHIBITOR; ROFECOXIB; ANTIRHEUMATIC AGENT;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; ECONOMIC ASPECT; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE QUALITY; KNEE OSTEOARTHRITIS; METHODOLOGY; PHARMACOECONOMICS; REVIEW; RHEUMATOLOGY; STANDARD; STATISTICAL MODEL;

ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMIC; OSTEOARTHRITIS, KNEE; PROGRAM EVALUATION; REFERENCE STANDARDS; RHEUMATOLOGY;

EID: 0347650292     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Gabriel SE, Tugwell P, Drummond M. Progress towards an OMERACT-1LAR guideline for economic evaluations in rheumatology. Ann Rheum Dis 2002;61:370-3.
2. Gold MR, Siegel JC, Russell LB, Weinstein MC. Cost-effectiveness analysis in health and medicine. New York: Oxford University Press; 1986.
3. Maetzel A, Tugwell P, Boers M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
4. Kamath CC, Kremers HM, Vanness DJ, 0'Fallon WM, Cabanela RL, Gabriel SE. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003;6:144-57.
5. Torrance GW, Raynauld JP, Walter V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis: economic results. Osteoarthritis Cartilage 2002;10:518-27.
6. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J. Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15:1833-40.
7. Boyle MH, Furlong W, Feeny D, Torrance GW, Hatcher J. Reliability of the Health Utilities Index - Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res 1995;4:249-57.
8. Maetzel A, Krahn M, Naglie G. The cost-effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003;49:283-92.
9. Ades AE, Cliffe S. Markov chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty. Med Decis Making 2002;22:359-71.
10. Gabriel S, Drummond M, Maetzel A, et al. OMERACT 6 Economics Working Group Report: A proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90.
11. National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors. Technical Appraisals Process Series No. 5. London: NICE; 2000.
12. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001;4:225-50.
13. Raynauld J-P, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis: clinical results. Osteoarthritis Cartilage 2002;10:506-17.
14. Simon GE, Vonkorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-902.
15. National Institute for Clinical Excellence. Cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology appraisal No. 27, August 2001. London: NICE; 2001. Also available at: http://www.nice.org.uk/cat.asp?c=18033 [Cited August 14, 2003]